Contents

Search

mobocertinib (Exkivity)

Indications: - 2nd-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations * amivantamab (Rybrevant) is the only other FDA-approved therapy for NSCLC with EGFR exon 20 insertion mutations Adverse effects: - diarrhea (91%), rash (45%), paronychia (38%), decreased appetite (35%), nausea (34%), dry skin (31%), vomiting (30%), increased serum creatinine (25%), stomatitis (24%), pruritus (21%) * boxed warning: QTc prolongation & Torsades de Pointes * warnings & precautions for interstitial lung disease/pneumonitis, cardiac toxicity, & diarrhea

Interactions

drug adverse effects of tyrosine kinase inhibitor(s)

General

small inhibitory antineoplastic agent (ib drug) tyrosine kinase inhibitor

References

  1. Bassett M FDA OK's New Drug for Lung Cancers With Exon 20 Mutations. First approval for oral targeted therapy mobocertinib (Exkivity). MedPage Today September 16, 2021 https://www.medpagetoday.com/hematologyoncology/lungcancer/94539